ASX news
TruScreen Group (NZX/ASX:TRU) has launched a 5-year program to screen 260,000 women for cervical cancer using its AI-enabled, real time, non-invasive, cervical cancer screening device.
🩺The 5-year cervical cancer screening program was launched in Ho Chi Minh City on 12 April 2025, aiming to screen 260,000 women.
🩺 The program uses TruScreen’s AI-enabled, real-time, non-invasive screening device, eliminating the need for lab infrastructure.
🩺 Partnership between TruScreen, Ho Chi Minh City Public Health Association and Gorton Health Services supports Vietnam’s goal to screen 60% of women aged 30-54.
"This program with its target of screening 260,000 women may save the lives of over 2,600 mothers, daughters, sisters, wives and friends.” Marty Dillon, CEO of TruScreen
TruScreen Group (NZX/ASX:TRU) has launched a 5-year program to screen 260,000 women for cervical cancer using its AI-enabled, real time, non-invasive, cervical cancer screening device.
🩺The 5-year cervical cancer screening program was launched in Ho Chi Minh City on 12 April 2025, aiming to screen 260,000 women.
🩺 The program uses TruScreen’s AI-enabled, real-time, non-invasive screening device, eliminating the need for lab infrastructure.
🩺 Partnership between TruScreen, Ho Chi Minh City Public Health Association and Gorton Health Services supports Vietnam’s goal to screen 60% of women aged 30-54.
"This program with its target of screening 260,000 women may save the lives of over 2,600 mothers, daughters, sisters, wives and friends.” Marty Dillon, CEO of TruScreen
NeuroScientific Biopharmaceuticals (ASX:NSB) has acquired the patented StemSmartTMstem cell technology from Isopogen WA to deliver potent and clinically promising cellular medicine for immune-related diseases.
🔬Exclusive rights secured to patented StemSmartTM stem cell technology for treating inflammatory and immune-related diseases
🔬StemSmartTM interacts with immune system to modulate immune responses
🔬Strong early trial results in patients with Crohn’s disease and other serious conditions, with multiple positive clinical responses
“We’re incredibly excited to add mesenchymal stem cell technology to our growing portfolio. This acquisition not only complements our existing pipeline of therapeutic peptides, but also strategically positions us at the forefront of next-generation biologics.” – Dr Anton Uvarov, Founding Director of NeuroScientific
NeuroScientific Biopharmaceuticals (ASX:NSB) has acquired the patented StemSmartTMstem cell technology from Isopogen WA to deliver potent and clinically promising cellular medicine for immune-related diseases.
🔬Exclusive rights secured to patented StemSmartTM stem cell technology for treating inflammatory and immune-related diseases
🔬StemSmartTM interacts with immune system to modulate immune responses
🔬Strong early trial results in patients with Crohn’s disease and other serious conditions, with multiple positive clinical responses
“We’re incredibly excited to add mesenchymal stem cell technology to our growing portfolio. This acquisition not only complements our existing pipeline of therapeutic peptides, but also strategically positions us at the forefront of next-generation biologics.” – Dr Anton Uvarov, Founding Director of NeuroScientific
AML3D Limited (ASX:AL3) has announced the largest custom ARCEMY® system ever built. The system was installed at the US Navy’s AM Center of Excellence in Danville VA, that has been setup and operated by Austal USA. Bringing the system online triggers payment of the final 50% of the contract value.
🇺🇲 The custom ARCEMY® system supports Austal USA’s drive to further embed additive manufacturing into the U.S. Navy’s supply chain.
🇺🇲 Austal USA leads and operates the Navy’s Additive Manufacturing Center of Excellence in Danville, Virginia, which currently operates a large scale ARCEMY® 6700 system delivered in early 2024.
🇺🇲 A second custom ARCEMY® system was recently installed, featuring a massive 11,000kg positioner and over four meters of linear rail, enabling a build volume of approximately 35 cubic meters—making it the largest of its kind
“The successful delivery the custom ARCEMY® system to Austal USA (refer to ASX announcement November 20,2023) aligns with our ambitions to expand the range of U.S.
defense work we do. AML3D already has a track record of deploying our WAM Additive Manufacturing technology in support of the U.S. Navy submarine industrial base. Those successes are translating to an adoption of additive manufacturing technology in the wider U.S. Marine Industrial Base, covering shipbuilding and munitions". - Sean Ebert, AML3D CEO
AML3D Limited (ASX:AL3) has announced the largest custom ARCEMY® system ever built. The system was installed at the US Navy’s AM Center of Excellence in Danville VA, that has been setup and operated by Austal USA. Bringing the system online triggers payment of the final 50% of the contract value.
🇺🇲 The custom ARCEMY® system supports Austal USA’s drive to further embed additive manufacturing into the U.S. Navy’s supply chain.
🇺🇲 Austal USA leads and operates the Navy’s Additive Manufacturing Center of Excellence in Danville, Virginia, which currently operates a large scale ARCEMY® 6700 system delivered in early 2024.
🇺🇲 A second custom ARCEMY® system was recently installed, featuring a massive 11,000kg positioner and over four meters of linear rail, enabling a build volume of approximately 35 cubic meters—making it the largest of its kind
“The successful delivery the custom ARCEMY® system to Austal USA (refer to ASX announcement November 20,2023) aligns with our ambitions to expand the range of U.S.
defense work we do. AML3D already has a track record of deploying our WAM Additive Manufacturing technology in support of the U.S. Navy submarine industrial base. Those successes are translating to an adoption of additive manufacturing technology in the wider U.S. Marine Industrial Base, covering shipbuilding and munitions". - Sean Ebert, AML3D CEO
Neuren Pharmaceuticals (ASX:NEU) has secured FDA confirmation of primary endpoints for its Phase 3 clinical trial of a new drug therapy to treat Phelan-McDermid Syndrome (PMS).
🧬 Between 8,000-15,000 have PMS, and there are no medication, drugs or therapies to treat it, causing an overwhelming unmet medical need
🧬 PMS affects a region of chromosome 22 that supports synapses in the brain, severely impacting quality of life
🧬 Neuren’s trial which commences in mid-2025 marks the first ever Phase 3 trial for PMS in children
“We are very pleased with the outcome of another constructive discussion with the FDA and are now excited to be able to move forward as planned with the first ever Phase 3 trial in children with Phelan-McDermid syndrome.” – Jon Pilcher, CEO of Neuren
Neuren Pharmaceuticals (ASX:NEU) has secured FDA confirmation of primary endpoints for its Phase 3 clinical trial of a new drug therapy to treat Phelan-McDermid Syndrome (PMS).
🧬 Between 8,000-15,000 have PMS, and there are no medication, drugs or therapies to treat it, causing an overwhelming unmet medical need
🧬 PMS affects a region of chromosome 22 that supports synapses in the brain, severely impacting quality of life
🧬 Neuren’s trial which commences in mid-2025 marks the first ever Phase 3 trial for PMS in children
“We are very pleased with the outcome of another constructive discussion with the FDA and are now excited to be able to move forward as planned with the first ever Phase 3 trial in children with Phelan-McDermid syndrome.” – Jon Pilcher, CEO of Neuren
Australian game developer Streamplay Studio (ASX:SP8) has reported strong first-quarter performance, with its subsidiary Noodlecake generating $2.7M in revenue and preparing to launch several high-profile games.
Subsidiary Noodlecake generated $2.7M revenue in Q1 following acquisition by Streamplay on 1 January 2025
Upcoming mobile title Super Flappy Golf has achieved over 50,000 pre-orders
Over 30 new game pitches and strategic partnerships explored at Game Developers Conference (GDC) 2025
“We’ve been very pleased with how seamlessly the Noodlecake team has integrated, and we’re now strongly focused on driving growth both organically and through the
identification of complementary assets to bring into the group.” — Bert Mondello, Chairman of Streamplay Studio
Australian game developer Streamplay Studio (ASX:SP8) has reported strong first-quarter performance, with its subsidiary Noodlecake generating $2.7M in revenue and preparing to launch several high-profile games.
Subsidiary Noodlecake generated $2.7M revenue in Q1 following acquisition by Streamplay on 1 January 2025
Upcoming mobile title Super Flappy Golf has achieved over 50,000 pre-orders
Over 30 new game pitches and strategic partnerships explored at Game Developers Conference (GDC) 2025
“We’ve been very pleased with how seamlessly the Noodlecake team has integrated, and we’re now strongly focused on driving growth both organically and through the
identification of complementary assets to bring into the group.” — Bert Mondello, Chairman of Streamplay Studio
Kincora Copper Limited (TSXV:KCC, ASX:KCC) has secured its second major earn-in with AngloGold Ashanti (JSE:ANG; NYSE:AU).The deal opens the way for more extensive exploration in the Northern Junee-Narromine Belt of the Macquarie Arc, Central West NSW, Australia.
⛏️ Multiple-year deal for the Nyngan South, Nevertire South and Mulla projects
⛏️ AngloGold Ashanti may earn a 70% interest by spending $25 million
⛏️Kincora remains the operator, receiving a 10% management fee
“We are very pleased to broaden our partnership with AngloGold Ashanti. It comes as we continue to progress our ongoing exploration program at the Nyngan project, with a ground gravity survey and hole twelve of the scout drilling program recently completed." - Kincora Copper Technical Committee chair, John Holliday and VP of Exploration Peter Leaman
Kincora Copper Limited (TSXV:KCC, ASX:KCC) has secured its second major earn-in with AngloGold Ashanti (JSE:ANG; NYSE:AU).The deal opens the way for more extensive exploration in the Northern Junee-Narromine Belt of the Macquarie Arc, Central West NSW, Australia.
⛏️ Multiple-year deal for the Nyngan South, Nevertire South and Mulla projects
⛏️ AngloGold Ashanti may earn a 70% interest by spending $25 million
⛏️Kincora remains the operator, receiving a 10% management fee
“We are very pleased to broaden our partnership with AngloGold Ashanti. It comes as we continue to progress our ongoing exploration program at the Nyngan project, with a ground gravity survey and hole twelve of the scout drilling program recently completed." - Kincora Copper Technical Committee chair, John Holliday and VP of Exploration Peter Leaman
The USA’s status as a global super-power is under the microscope and Teaminvest Private Group (ASX:TIP) CEO Andrew Coleman identifies where to invest as USA’s economic power wanes:
📉 Recession reality: TIP believes the US recession is no longer looming; it`s arrived and says "Liberation Day" may go down as the moment things truly unraveled.
🛠️ People and productivity: Since the 16th century, growth has come from more workers or more output per worker and TIP says shrinking the workforce and blocking innovation breaks that math.
🌪️ Defying economic gravity: TIP warns policies that ignore fundamentals might seem bold, but gravity doesn’t care if you believe in it, it happens.
The USA’s status as a global super-power is under the microscope and Teaminvest Private Group (ASX:TIP) CEO Andrew Coleman identifies where to invest as USA’s economic power wanes:
📉 Recession reality: TIP believes the US recession is no longer looming; it`s arrived and says "Liberation Day" may go down as the moment things truly unraveled.
🛠️ People and productivity: Since the 16th century, growth has come from more workers or more output per worker and TIP says shrinking the workforce and blocking innovation breaks that math.
🌪️ Defying economic gravity: TIP warns policies that ignore fundamentals might seem bold, but gravity doesn’t care if you believe in it, it happens.
What is the VIX, and why does it spike during a crash?
#finance #fintok #stocks #shares #investing #wallstreet #VIX #fear #trump #trumptariffs
What is the VIX, and why does it spike during a crash?
#finance #fintok #stocks #shares #investing #wallstreet #VIX #fear #trump #trumptariffs
Elsight Limited (ASX:ELS) has secured a US$4.28 million supply deal with its European-based defence OEM (original equipment manufacturer) customer for its AI-powered Halo connectivity platform.
📡 European defence drone OEM customer commits to US$4.28 million in additional purchases over next four months (April-July 2025)
📡 Deal follows the initial production order of US$300,000 last month and signifies an escalation in scale and scope of the engagement
📡 Initial production order allowed customer to conclude an extensive and successful field integration
“This commitment is a major validation of the value, reliability and strategic position of our solution. After a long and extensive period of field testing, the Customer’s fast move to production based on field deployment success, and already progressed to a multi-million-dollar scale-up phase within a few months, highlights just how critical reliable communications are in modern defence operations.” – Yoav Amitai, CEO of Elsight
Elsight Limited (ASX:ELS) has secured a US$4.28 million supply deal with its European-based defence OEM (original equipment manufacturer) customer for its AI-powered Halo connectivity platform.
📡 European defence drone OEM customer commits to US$4.28 million in additional purchases over next four months (April-July 2025)
📡 Deal follows the initial production order of US$300,000 last month and signifies an escalation in scale and scope of the engagement
📡 Initial production order allowed customer to conclude an extensive and successful field integration
“This commitment is a major validation of the value, reliability and strategic position of our solution. After a long and extensive period of field testing, the Customer’s fast move to production based on field deployment success, and already progressed to a multi-million-dollar scale-up phase within a few months, highlights just how critical reliable communications are in modern defence operations.” – Yoav Amitai, CEO of Elsight
Guzman y Gomez (ASX:GYG) has reported a strong quarterly performance across its international fast food network over the third quarter on the back of its mission to, "reinvent fast food and change the way the masses eat".
🌮 Restaurant network expansion continued, with three new GYG restaurants in Australia and two in the US
🌮 Marketing initiatives introduced new menu item Street Corn, and Clean is the New Healthy campaign in the US
🌮 Acceleration of sales recorded during breakfast period and after 9pm
Guzman y Gomez (ASX:GYG) has reported a strong quarterly performance across its international fast food network over the third quarter on the back of its mission to, "reinvent fast food and change the way the masses eat".
🌮 Restaurant network expansion continued, with three new GYG restaurants in Australia and two in the US
🌮 Marketing initiatives introduced new menu item Street Corn, and Clean is the New Healthy campaign in the US
🌮 Acceleration of sales recorded during breakfast period and after 9pm
Challenger (ASX:CGF), an Australian investment management firm focused on retirement income, has announced that Japanese insurance company Dai-ichi Life will become a new strategic shareholder.
🤝Dai-ichi Life, through its Australian subsidiary TAL, is acquiring a minority stake in Challenger Limited.
🤝The deal is subject to regulatory approval and marks Dai-ichi Life as a new strategic shareholder.
🤝Challenger and Dai-ichi Life plan to explore future opportunities together while maintaining existing partnerships.
“Dai-ichi Life is a global leader in life insurance and we look forward to building a relationship that will benefit both our customers and shareholders. We welcome their significant investment in our business and will explore future opportunities that support our strategic objectives.” – Nick Hamilton, CEO and MD of Challenger
ASX Announcement ⚡️https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02933387-2A1589613&v=7bc42bd11d853ed5e8c28f2ffcd6a069ee5cd6b4
Challenger (ASX:CGF), an Australian investment management firm focused on retirement income, has announced that Japanese insurance company Dai-ichi Life will become a new strategic shareholder.
🤝Dai-ichi Life, through its Australian subsidiary TAL, is acquiring a minority stake in Challenger Limited.
🤝The deal is subject to regulatory approval and marks Dai-ichi Life as a new strategic shareholder.
🤝Challenger and Dai-ichi Life plan to explore future opportunities together while maintaining existing partnerships.
“Dai-ichi Life is a global leader in life insurance and we look forward to building a relationship that will benefit both our customers and shareholders. We welcome their significant investment in our business and will explore future opportunities that support our strategic objectives.” – Nick Hamilton, CEO and MD of Challenger
ASX Announcement ⚡️https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02933387-2A1589613&v=7bc42bd11d853ed5e8c28f2ffcd6a069ee5cd6b4
Stocks have been dumped over the last week on Trump’s latest tariff moves, but is the recent rebound just a dead cat bounce, and what is a dead cat bounce?
#finance #stocks #stockmarket #US #wallstreet #wallst #trump #trumptariffs #tradewar #deadcatbounce #trading
Stocks have been dumped over the last week on Trump’s latest tariff moves, but is the recent rebound just a dead cat bounce, and what is a dead cat bounce?
#finance #stocks #stockmarket #US #wallstreet #wallst #trump #trumptariffs #tradewar #deadcatbounce #trading
Get the latest ASX stock market news delivered to your inbox
By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy